OCT 22, 2020 12:05 PM SGT

Incorporating NGS in an Asian non-small cell lung cancer (NSCLC) population - a cost-effectiveness analysis

Speaker
  • Oncology Fellow, Resident Physician, National Cancer Centre, Singapore
    Biography

      Aaron is currently an Oncology Fellow at the National Cancer Centre Singapore (NCCS), having completed his specialty training in Medical Oncology in Sydney, Australia. He also completed a PhD in cancer drug discovery at The University of Sydney. His current focus is in early phase clinical trials and lung cancer translational research. As an early career researcher, he has received numerous awards and achievements including an International Association for the Study of Lung Cancer (IASLC) Fellowship 2018-2020, ASCO 2018 and ESMO Asia 2019 Merit Awards.


    Abstract

    There is an expanding list of therapeutically relevant biomarkers for non-small cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition in scaling traditional single biomarker assays from small biopsies is an increasingly encountered problem. We compared the performance of targeted NGS panels with traditional assays and correlated the mutational landscape with PD-L1 status in Singaporean patients with the National Lung Profiling (NLP) study. A cost-effectiveness analysis of NGS compared to standard molecular testing was conducted. The study demonstrated that even in an EGFR mutant predominant population, upfront NGS represented a feasible, cost-effective method of diagnostic molecular profiling compared with sequential testing strategies. These results support the implementation of diagnostic NGS in non-squamous NSCLC in Asia to allow patients access to the most appropriate personalized therapy.

    Learning Objectives:
    1. To recognise key considerations for the routine clinical implementation of next-generation sequencing
    2. To appraise the cost-effectiveness of diagnostic next-generation sequencing for metastatic lung cancer


    Show Resources
    You May Also Like
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    NOV 19, 2020 8:00 AM GMT
    C.E. CREDITS
    NOV 19, 2020 8:00 AM GMT
    Date: November 19, 2020 Time: 12:00am (PDT), 9:00am (CET), 4:00pm (SGT) We present split-FISH, a multiplexed fluorescence in situ hybridization method that leverages a split-probe design to...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 30, 2021 8:00 AM PDT
    MAR 30, 2021 8:00 AM PDT
    DATE: March 30, 2021 TIME: 08:00am PST In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effect...
    Loading Comments...
    Show Resources